



**Elisabeth Stampa, Board Member at Medichem and President Medicines for Europe**

With more than twenty years in the industry and as an experienced business leader with track record in growing and transforming businesses, Elisabeth serves currently at the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player. She held other executive positions at Corporate family business (Medichem SA and the former Combino Pharm SL), having started her career at Laboratorios Esteve. She holds a BSc in Pharmacy (UB, Spain) and a MBA (ESADE, Barcelona, Spain). She also serves on the Board of Trustees at the IQS in Barcelona. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry at a global level.



**Paul Neill, Chairperson, Medicines for Ireland, Director of Generic Medicines, Teva Pharmaceuticals Ireland**

Paul is the Director of Generic Medicines for Teva Pharmaceuticals Ireland, the largest supplier of prescription medicines to the State. Paul brings with him a wealth of practical experience gained from almost twenty years in various commercial roles in the Pharmaceutical Market – ten of these in leadership roles in Teva.



**Stella Kyriakides, Commissioner for Health and Food safety, European Commission**

As European Commissioner for Health and Food Safety, Stella Kyriakides has been leading the Commission's work on the public health response to COVID-19. Commissioner Kyriakides is responsible for a number of initiatives in the area of health aiming to establish a strong European Health Union.

These include Europe's Beating Cancer Plan, the implementation of the EU Pharmaceutical Strategy, the proposal for a

European Health Data Space and the operationalisation of the EU4Health Programme. She is a strong advocate for mental health. Commissioner Kyriakides is also responsible for the 'Farm to Fork' strategy for sustainable food, covering every step in the transformation of the food chain from production to consumption. Her responsibilities include animal welfare, food safety and animal and plant health and leading the work to protect plant health and reducing dependency on pesticides. Since February 2022, Commissioner Kyriakides has been at the forefront of EU efforts to support Ukraine and its people in the area of health, including by supporting the protection of the physical and mental health of Ukrainian refugees arriving in Member States. In 2006-2019, she was elected to the Cyprus Parliament for the Democratic Rally party, of which she was the Vice-President for ten years. In 2011, she was appointed Head of the Cyprus Delegation to the Parliamentary Assembly of the Council of Europe (PACE). In 2017, she was elected President of the PACE, the fourth woman to hold this position in the history of the Assembly. She has been an active advocate on patients' rights, and on the rights of cancer patients, founding the first Cypriot breast cancer organisation Europa Cyprus, for which she served as President for over 15 years. She was elected President to the European Breast Cancer Coalition Europa Donna, and served on numerous European patient advocacy and scientific boards. She is the recipient of numerous awards from her community service in Cyprus and globally.



**Stephen Donnelly, Minister for Health, Ireland**



**Maja Graf, Associate Director Policy & Market Access, Medicines for Europe**

Maja Graf is an Associate Director Policy & Market Access for Medicines for Europe, a trade association representing the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries. In her role, she focuses on issues such as equitable access to affordable treatments across Europe, achieved by sustainable pharmaceutical market for off-patent medicines and innovation throughout the medicines life cycle, in the form of Value Added Medicines. She holds the Master of Sciences of Pharmacy degree obtained from Faculty of pharmacy, University of Ljubljana. Before joining Medicines for Europe, she worked in the pharmaceutical industry. Medicines for Europe is a leading partner for better healthcare aims to increase the health and wellbeing of all Europeans through better access to high-quality medicines.



**Max Newton, Engagement Manager, IQVIA**

Max Newton, based in London, England, United Kingdom, is currently a Engagement Manager at IQVIA, bringing experience from previous roles at IQVIA. Max Newton holds a 2014 - 2015 Master's Degree in MSc Drug Discovery & Pharma Management (with Distinction) @ UCL. With a robust skill set that includes Management, Leadership, Derivatives, Public Speaking, Investment Banking and more, Max Newton contributes valuable insights to the industry.



**John Darby, Executive Director, Lachman Consultants**

John Darby is a goal directed, results-focused executive professional with a strong, global background in quality assurance, compliance, audits, training, and remediation. His 18+ years of experience and keen insight contribute to his ability to identify issues and form innovative solutions and strategies for continued success. Mr. Darby has been responsible for the management, organization, and strategic guidance of global, quality and operations-based training functions. He is proficient in sterile pharmaceutical manufacture, oral solid dose manufacture and API manufacture.



**Deirdre Kelly, Vice-chair Medicines for Ireland, Country Manager Consilient Health**

Deirdre joined Consilient Health in 2014 to set up the Irish business unit. Since then, Deirdre and the Irish team have successfully launched a range of medicines across CH's key therapeutic areas in both the secondary and primary care settings with new launches in Malta from 2021. Prior to joining Consilient Health, Deirdre spent 13 years at Eli Lilly, most recently as business unit manager responsible for the Osteoporosis, Cardiology, Oncology and Primary Care product portfolios. At Novo Nordisk, she was the lead marketer for growth hormone in the UK & Ireland territories. Deirdre started her career at Nutricia where she held a number of management positions. Deirdre has a BSc (Hons) in Nutrition & Dietetics from Trinity College, Dublin with post graduate qualifications in marketing, health economics and a Diploma from the Institute Of Directors. Deirdre is also a board member of Medicines For Ireland trade association, Irish Medicines Verification Organisation and is completing her term as President of the Irish Pharmaceutical Managers Institute (2022 / 2023).



**Prof Michael Barry, National Clinical Lead, Medicines Management Programme, Ireland (inv)**

Prof. Michael Barry is a Consultant Clinical Pharmacologist and Head of the Department of Pharmacology & Therapeutics at the University of Dublin, Trinity College. He is the clinical director of the National Centre for Pharmacoeconomics which conducts pharmacoeconomic evaluations on medicines prior to reimbursement under the Community Drugs schemes in Ireland. He is Past-President (2010-2011) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He was a board member of the Health Information and Quality Authority (HIQA) and is a member of a number of National Committees on pricing and reimbursement of medicines. Prof. Barry chairs the New Drugs Committee and the Medication Safety Committee at St. James's Hospital, Dublin. In 2013 he was appointed as Clinical Lead for the new HSE Medicines Management Programme. He is a fellow of the Royal College of Physicians in Ireland and is a specialty trainer for Pharmacology & Therapeutics. His research areas include the cost-effectiveness of high cost drugs including chemotherapeutic agents and biologic drugs, pricing and reimbursement and performance based risk sharing schemes. He has published widely on the cost-effectiveness of medicines in the Irish healthcare setting.



**Arnaud Maheas, Chair of Generic Market Access Committee, Medicines for Europe, Director Public Affairs Europe, Sandoz**

Arnaud is a highly experienced public affairs professional with a successful track record across multiple industries. He built and led the European public affairs practice at Servier. And prior to joining the healthcare industry 15 years ago, he headed the EU representation of the French national railway company (SNCF) and later managed strategic relations with the EU for the association of the top 100 companies operating in France (AFEP). Arnaud holds a Master of Arts in European Administration and Politics from the College of Europe in Bruges and degrees in European Law and Government Affairs from the University of Rennes and Sciences Po Rennes.



**Victor Mendonça, Head of Corporate Affairs, Viatriis**

Victor Lino Mendonça is the Head of Corporate Affairs for Viatriis in Europe and Board member of Medicines for Europe. Formerly, he was leading the Health Economics department at Medicines for Europe. He was also Advisor to the Executive Board of INFARMED for almost 8 years and prior to this, was the Advisor to the Health Secretary of State to the Ministry of Health in Portugal. He has more than 20 years of experience in pharmaceuticals sector having also worked in FMCG sector. Victor graduated in Business Administration by Universidade Católica Portuguesa in Portugal.

**Olivier Girard, DG HERA, European Commission**



**Laure Geslin, DG Sante, European Commission (inv)**

Laure Geslin is Policy Officer at the European Commission's Directorate-General for Health and Food Safety (DG SANTE). She is leading a team focused on EU level policy developments related to the accessibility, affordability, and availability of medicines, and is responsible for steering EU-wide cooperation in relation to pricing and reimbursement of medicines. Prior to this role, Laure served as Head of Division for Proper Use at the Belgian Federal Agency for Medicines and Health Products (FAMHP), where she chaired the Belgian Task Force for Medicines Shortages and represented the agency in the EMA/HMA Task Force on Availability of Authorised Medicines and the Belgian Pricing Committee for Pharmaceutical Products. She previously worked as Director of Tarification Services and Professional Development and Defence at Pharmacy. Brussels, and advocated for community pharmacists in Brussels. Laure started her career as community pharmacist and holds a Master's degree in Pharmaceutical Science from the University of Ghent, Belgium.

**Irish Pharmacy Union and Executive member, PGEU (inv)**



**Philippe Drechsle, Vice President EU Portfolio, Teva**

Economist and certified accountant by education, Philippe has been working in the generics industry for over 20 years in various functions spanning from controlling/finance, demand management, product administration, area management, business development, product portfolio optimization, to special projects such as FMD project lead. He is currently responsible for EU Portfolio, in charge of generics product selection, launches and life-cycle management.

**Ellen McGrath, Medicines Shortages Coordination Lead, Health Products Regulatory Authority (HPRA)**



**Nina Uldal, Director of Procurement, Amgros (inv)**

Nina Uldal is currently Director of Procurement at Amgros I/S, Copenhagen, Denmark, which secures the supply of medicines and hearing aids to the public hospitals and hearing clinics in Denmark. She has a Master of Public Governance, Organizational Leadership, from the Copenhagen Business School. In 2019, she graduated from the Innovation Leadership Challenge Programme (ILC) from the University of California, Berkeley. The focus is on leading innovation in the healthcare sector. In 2007, she graduated the Advanced Business Development programme from INSEAD and Oxford University in cooperation with Danish Centre for Leadership, an executive programme with focus on strategic business development and implementation as well as personal leadership and organisational development.

**Irish development agency (IDA) (tbc)**



**Emer Cooke, Executive Director, European Medicines Agency**

Emer Cooke began her mandate as Executive Director of EMA on 16 November 2020.

Ms Emer Cooke has over 30 years of experience in international regulatory affairs, with more than 18 of these in leadership roles. Before taking up her current role, she was the Director responsible for all medical product related regulatory activities at the World Health Organization (WHO) in Geneva between November 2016 and November 2020. Ms Cooke worked at EMA between 2002 and 2016. She joined the Agency as Head of Inspections and became Head of International Affairs in 2009. Prior to that, she was Principal Administrator in the Pharmaceuticals Unit of the European Commission between 1998 and 2002, with responsibility for inter alia, inspections, international activities including enlargement of the EU and selected legislative initiatives. Ms Cooke worked for the European Federation of Pharmaceutical industries and Associations (EFPIA) as Manager of Scientific and Regulatory Affairs from 1992 to 1995 and part time from 1996 to 1998. She also worked part time as an independent pharmaceutical policy advisor, based in the Czech Republic, from 1996 to 1998. Ms. Cooke held a number of roles within the Irish pharmaceutical sector between 1985 and 1990 including two years as a pharmaceutical assessor at the Irish medicines regulatory authority. Ms. Cooke holds a degree in pharmacy and two master's degrees in science and in business administration from Trinity College Dublin, Ireland. She is an Irish national.



**Aidan Fry, Director External Communications, STADA**

Aidan Fry is Director of External Communications at STADA Arzneimittel. In this role, which he has held since February 2020, Aidan oversees communications with key stakeholders across the group’s 120-plus markets and activities encompassing generics, specialty medicines and consumer healthcare products. He also coordinates STADA’s participation in key industry associations, including Medicines for Europe and the International Generic and Biosimilar medicines Association. Aidan has more than 20 years of experience in the off-patent medicines sector, including as a co-founder and editor of Generics Bulletin, the industry-leading business-to-business newsletter.



**Tom Roane, Vice President, Corporate Engagement & Strategy, Direct Relief**

Tom Roane serves as Vice President of Corporate Engagement & Strategy for the global medical relief non-profit Direct Relief, an organization founded over 70 years ago which will provide over \$2 Billion this year in donated medical products to vetted and qualified public hospitals and clinics in over 100 countries around the world, including within Europe and the United States. Roane has over two decade’s experience in establishing and managing Rx access and medical support programs in all regions of the world to help underserved patients access their required treatments, as well as 8 years’ experience in business development and marketing management with big pharma and start up biotechnology companies. His expertise in the design and implementation of creative and impactful ESG programs have opened opportunities for drug access for underserved patients with cancer, diabetes, rare disease, and non-communicable diseases. All of the world’s largest pharmaceutical corporations have trusted relationships with Direct Relief, which has become the largest global non-profit provider of humanitarian medical relief for the world’s at-risk and underserved, including in Ukraine where Direct Relief is working hand in hand with the country’s health ministry and other strategic partners in providing into Ukraine many hundreds of tons of requested and required vital medical products.



**Adele Paterson, CEO, International Health Partners**

As CEO of the global health charity International Health Partners (IHP), Adele leads its work to increase access to essential healthcare products for those in vulnerable and disaster hit communities. Last year, IHP delivered 14.5 million treatments supporting 6.8m people in 31 countries. Under Adele’s leadership, IHP has initiated rigorous ways to measure the long-term impacts of its work; quadrupled the number of treatments shipped; established a secure, diverse and growing income stream; and has developed an software business bringing supply chain efficiencies, best practice and impact measurement to product donations. Adele joined IHP after working as head of policy for a financial trade association and prior to this, headed CSR, fundraising and communications for a national regeneration charity. An

economics and politics graduate, she started her career as a political researcher, running the parliamentary office of a UK government minister. Adele is Treasurer of Integral Alliance, a union of 22 global disaster response agencies, and sits on the Board of the Anglican Communion Fund supporting the international ministry of the Archbishop of Canterbury in 165 countries.



**Prof Derek O'Keeffe, Physicianeer, Consultant Clinician/Surgeon (inv)**

Prof Derek O'Keeffe is a Physicianeer, who holds dual first-class honors degrees and doctorates in Medicine and Engineering. In addition he holds several gold medal awards across STEM and a first-class honors MBA degree. He was a Fulbright Scholar at Harvard, a Green Templeton Scholar at Oxford and is a graduate of the Endocrinology Clinical Fellowship at the Mayo Clinic, USA. He has multiple academic publications, biomedical patents and several international research prizes. He has previously worked with NASA placing a sleep experiment onboard the International Space Station and was their flight surgeon for a NEEMO Aquarius mission. He is founder and director of the Health Innovation via Engineering (HIVE) Lab which develops patient centred solutions to clinical problems from bedside to bench to bedside through interdisciplinary collaboration. He has explored over 100 countries, volunteered extensively & was awarded The Outstanding Young Person of the World by Junior Chamber International. He is a Black Belt Taekwondo Instructor, Qualified Pilot, DJ, Advanced Scuba Diver, Triathlete & Six-Star Medal Marathoner. He has designed an award winning Cardiovascular themed garden for Bloom in the Phoenix Park and is a Guinness World Record Holder. He is a Consultant Physician (Endocrinologist) at University Hospital Galway and is the Professor of Medical Device Technology at the University of Galway. He is currently the HSE National Clinical Lead for Diabetes.



**James Burt, Chair of Value Added Medicines Sector Group, CEO of Pharmanovia**

James joined Pharmanovia in October 2021. Before joining he was the Executive Vice President EMENA at Accord Healthcare and oversaw branded and generic pharmaceutical activities across 65 markets. Prior to this, he served as Vice President Hospital Business at Actavis, where he was responsible for the strategic direction of secondary-care activities worldwide. He holds a PhD in Chemical Engineering from the University of Birmingham, with a particular focus on biopharmaceutical manufacturing. James is Vice-Chair of the Medicines for Europe, Value Added Medicines Sector Group.





**Stefano Collatina, Country Lead, Italy and Pharmaceuticals Business Unit Head Southern Europe, Baxter**

Stefano Collatina graduated in Medicine in Rome in 1987 and had his 34 years career development in Healthcare Industry, either in Italy and in the US, mostly in Multinational organizations like Bristol-Myers Squibb, Merck, Schering AG and Baxter. His experience ranged from Medical to Sales and Marketing roles, from Business Development to Market/Patient Access, from Open Innovation to General management. Stefano's key competences are at the intersection of Medicine, Business and Technology. Stefano has a record of several product launches in different therapeutic areas, with a strong operation background obtained through the management of different Business Units. Stefano is currently the Country Lead at Baxter SpA, and, at the same time, is the Head of Baxter Integrated Care Solution Unit and Digital Head for South Europe, coordinating the efforts of Baxter GAPP, Market Access, Key and Strategic Account Management with the objective to develop and implement initiatives that will deliver sustainable value to the healthcare stakeholders. In addition Stefano is contributing to the development of Value Solutions within the ICS European Team, and is leading several projects of clinical pathways and digital optimization in South Europe Area (Italy, Greece, Spain, Portugal, France and Malta). Stefano is member of the Board of Equalia, the Italian Association representing the Generic Drugs Industries, and Vice-President and Chairman of the Italian Biosimilar Group.

**Parkinsons Europe (inv)**



**Silke Oeschger-Delautre, Corporate Communication Lead, Dr. Reddy's**



**Keith Moore, Sustainable Healthcare Alliance, UK**

Keith Moore MSc MIEMA CEnv is a freelance consultant with over twenty years corporate experience in strategic energy, carbon, environmental and sustainability management. Keith is based in South Devon, serving the South West and Nationally.



**Courtney Soulsby, Global Director Healthcare and Life Sciences Sector, BSI**

Courtney Soulsby works as a Global Director for the Healthcare and Life Sciences sector team for BSI (British Standards Institution). Working to understanding market challenges and future needs of the healthcare sector, Courtney works with key clients and industry partners to develop holistic solutions, strategies and programs. Courtney has worked with pharmaceutical industry and their downstream logistics supply chain for over ten years – with a deep understanding the issues with regulation, compliance, quality, and other risk exposures when transporting medicines.



**Ines Windisch, Head of Communications, Corporate Affairs and Sustainability, Zentiva**

Ines Windisch has extensive work experience in various roles within communication, public affairs, human resources, and sustainability. Ines started their career at Ludwig Merckle GmbH before moving to STADA Group and then ORF as a Live-Typer. In 2000, they joined Sanofi, where they held several positions, including Director of Communication and Associate Vice-President of Communication & Public Affairs. In 2018, Ines Windisch began working at Zentiva, where they served as Head of Corporate Affairs, Head of Corporate Affairs & Human Resources, Head of HR, Communications & Sustainability, and currently holds the position of Head of Communications, Corporate Affairs & Sustainability. Ines Windisch holds a Master of Business Administration (MBA) degree in Health Care Management from WU (Vienna University of Economics and Business). Ines also obtained a Matura degree from the Commercial College.

**Maja Anette Flønes Monsen, Norwegian Hospital Procurement Fund, Skyehusinnkop**



**Pierluigi Antonelli, CEO, Fresenius Kabi**

As President and CEO of Fresenius Kabi since March 2023, Pierluigi Antonelli is at the forefront in helping create and lead the next step in our company's strategic roadmap. During his distinguished career, he has held leading positions at numerous international corporations, including Novartis Oncology, Sandoz, Merck & Co, Bristol-Myers Squibb, McKinsey & Company and as CEO of Angelini Pharma. He holds an MBA from Kellogg School of Management and a degree in Business and Economics from L.U.I.S.S.



**Markus Sieger, CEO, Polpharma Group**

He holds a degree in Economics and has been working in emerging industries, such as information technology in Switzerland and United States and in emerging markets such as Singapore, Poland and CIS countries. Since the mid-nineties he has successfully managed complex and strategic transactions in and outside of Poland in the pharmaceutical industry, FMCG and media and has been a member of the supervisory board of several of those companies. He has been associated with Polpharma Group since 2000 and was appointed President of the Management Board in June 2016. In 2018, he joined the Executive Committee of Medicines for Europe.



**Rebecca Guntern, President Europe, Sandoz**

Rebecca joined Sandoz as Head of Sales in 2007 and has spent the last twelve years in leadership roles. In January 2020 she took over the role as Head Sandoz Europe. Prior she led one Cluster within the Region Europe incl. the countries UK, NL, CH, Iberia, Baltics & Israel - and before the BACH countries Belgium, Austria & Switzerland. Previously she was Country Head for Spain, Cyprus and Switzerland. Before joining Sandoz Rebecca worked for Bähler Apotheken as Deputy Head & Group Project Manager, for Merck Sharp & Dohme as Marketing & Sales Manager and for Roche Pharma as Clinical Research & Sales Representative. Rebecca joined the Executive Committee of Medicines for Europe in June 2019. She is vice-president of the association and takes a leading role in shaping the accessibility and affordability of off-patent medicines, with a strong focus on biosimilars. Rebecca Guntern received her Master degree in pharmacy at the University of Basel. She is a Member of the Board of Pharmasuisse, Swiss/American “Young Leaders Group”, Sciences industries, Société Suisse des Explosifs, Berner Kernkraftwerke and Medicines for Europe.



**Stephan Eder, Executive Vice President Western Europe & Germany, STADA**



**Artur Cwiok, Head of Europe, Viatris**

Artur Cwiok has over 31 years experience in the pharmaceutical industry. He has held senior leadership roles across Europe, leading in the innovative specialty sector and across all channels: generics, brands, OTC, retail, and hospital. Dr. Cwiok is currently serving as the Head of Europe for Viatris, one of the world's leading global pharmaceutical companies, empowering people worldwide to live healthier at every stage of life. Viatris is present in 38 countries in the European region and in more than 165 countries and territories globally. Dr. Cwiok actively represents his company in national and regional industry associations, helping shape policies that enable the European population to have access to high quality medicine. He is currently serving as a Member of the Executive Committee for Medicines for Europe. Dr. Cwiok is passionate about providing universal access to medicine and giving everyone the opportunity to live the healthiest life possible.



**Steffen Saltofte, CEO, Zentiva**